Download Image
    
Share
  
Post
Avdoralimab for COVID-19
1 study with 207 patients
Hospital Icon Control
Hospital Icon Avdoralimab Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Avdoralimab studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -68% Mortality -68% RCTs -68% Late -68% Favorsavdoralimab Favorscontrol
Oct 10
2022
 Carvelli et al., Critical Care Medicine, doi:10.1097/CCM.0000000000005683 Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])
68% higher mortality (p=0.13). RCT 207 hospitalized COVID-19 patients showing no significant benefit with avdoralimab, a C5a receptor (C5aR1) inhibitor, compared to placebo across three cohorts of patients with varying COVID-19 severity.